Doximity, Inc. (NASDAQ:DOCS) Shares Sold by Bellevue Group AG

Bellevue Group AG cut its stake in shares of Doximity, Inc. (NASDAQ:DOCS) by 59.7% in the 3rd quarter, Holdings Channel.com reports. The firm owned 29,060 shares of the company’s stock after selling 43,095 shares during the period. Bellevue Group AG’s holdings in Doximity were worth $1,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Verition Fund Management LLC raised its position in Doximity by 7.8% during the 3rd quarter. Verition Fund Management LLC now owns 42,812 shares of the company’s stock worth $1,865,000 after buying an additional 3,088 shares during the last quarter. MetLife Investment Management LLC raised its holdings in Doximity by 0.6% during the third quarter. MetLife Investment Management LLC now owns 65,064 shares of the company’s stock worth $2,835,000 after purchasing an additional 363 shares in the last quarter. FMR LLC raised its holdings in Doximity by 30.5% during the third quarter. FMR LLC now owns 6,837,733 shares of the company’s stock worth $297,920,000 after purchasing an additional 1,598,602 shares in the last quarter. West Tower Group LLC purchased a new stake in Doximity in the 3rd quarter valued at approximately $174,000. Finally, Harvest Fund Management Co. Ltd boosted its holdings in Doximity by 197.1% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 9,020 shares of the company’s stock valued at $393,000 after purchasing an additional 5,984 shares in the last quarter. 87.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DOCS has been the topic of a number of recent analyst reports. Needham & Company LLC raised Doximity from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a report on Friday, August 9th. Evercore ISI increased their price target on shares of Doximity from $34.00 to $45.00 and gave the company an “in-line” rating in a report on Tuesday, October 8th. Barclays boosted their price objective on shares of Doximity from $52.00 to $75.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Wells Fargo & Company raised shares of Doximity from an “underweight” rating to an “equal weight” rating and increased their target price for the company from $19.00 to $41.00 in a report on Friday, November 8th. Finally, Morgan Stanley raised Doximity from an “underweight” rating to an “equal weight” rating and boosted their price target for the stock from $33.00 to $53.00 in a research note on Thursday, November 14th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $52.27.

Doximity Price Performance

Shares of NASDAQ DOCS opened at $53.00 on Friday. The company has a 50-day simple moving average of $45.86 and a 200-day simple moving average of $36.09. The company has a market cap of $9.89 billion, a PE ratio of 58.24, a price-to-earnings-growth ratio of 4.25 and a beta of 1.30. Doximity, Inc. has a 12 month low of $22.96 and a 12 month high of $61.75.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.